MetaCap

Alpha Cognition Inc. (ACOG)

NASDAQ: ACOGHealthcareBiotechnologyUSD

9.00+0.15 (+1.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ACOG stock chart

Technical analysis

Key statistics

All statistics
Market cap
$198.37M
EPS (TTM)
-$1.32
52-week range
4.50 – 10.14
Day range
8.58 – 9.10
Volume / Avg
269.67K / 118.91K
Beta
—

52-week range

$4.50$10.14

ACOG stock today

Alpha Cognition (ACOG) closed at $9.00 on Nov 20, up 1.69% (+$0.15), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 269.67K shares, a sign of unusually heavy trading. At this level, ACOG sits in the middle of its 52-week range of $4.50 to $10.14: 11.2% below the high, set on Aug 24, 2026 and 100.0% above the low.

ACOG is up 38.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 56.5%. Alpha Cognition has posted a net loss over the last twelve months (EPS of -$1.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alpha Cognition

Company profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.

Industry
Biotechnology
CEO
Mr. Michael E. McFadden B.B.A.
Headquarters
Grapevine, TX
Employees
71

Financial highlights

Full financials

In fiscal 2025, Alpha Cognition generated $10.2 million in revenue. Alpha Cognition reported a net loss of $20.7 million, compared with a loss of $14.8 million a year earlier. Gross margin was 94.1% and operating margin -221.7%.

Alpha Cognition annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$10.22M——
Growth———
Net income$-20.67M$-14.79M$-13.76M
EPS (diluted)$-1.18$-2.04$-3.84

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$18.20+102.22%

  • Strong buy 3
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.30 vs $-0.33
Surprise
+9.09%

ACOG news

All ACOG news

Indexes, lists and sector

Appears in lists

Largest Healthcare stocks

Alpha Cognition stock FAQ

What is Alpha Cognition's stock price today?

ACOG last traded at $9.00 as of Nov 20, 4:00 PM EST, up 1.69% on the day. Prices are delayed at least 15 minutes.

Who is Alpha Cognition's CEO?

Mr. Michael E. McFadden B.B.A. is the chief executive officer of Alpha Cognition Inc., which has about 71 employees.

What is the ACOG 52-week high?

The 52-week high for ACOG is $10.14 and the 52-week low is $4.50. The stock is currently 11.2% below its high.